Hikma, Sciecure Pharma ink deal for niche injectable anti-viral medicines

BY Sandra Levy

Hikma Pharmaceuticals has reached a license, supply and distribution agreement between its wholly-owned subsidiary Hikma Pharmaceuticals International and Beijing Sciecure Pharmaceutical, a leading Chinese company that researches, develops and manufactures pharmaceutical products for global markets.

The agreement provides Hikma with exclusive rights to sell one of Sciecure’s niche injectable anti-viral medicines across the U.S. for a minimum of eight years, with an option to extend this partnership for an additional two years.

Sciecure expects to file this product for approval with the US Food and Drug Administration in early 2019.

“We are thrilled to partner with Sciecure, an innovative and vertically integrated company capable of producing high-quality products across the pharmaceutical spectrum from API to finished doses,” Hikma executive vice president of commercial and business development Daniel Motto said. “Our partnership with Sciecure is another example of how Hikma is continuing to expand its pipeline, targeting both niche products and high-volume opportunities, in order to offer a broad portfolio of high-quality medicines to US patients, physicians and hospitals.”


Leave a Reply

No comments found



What area is your company focused most on in 2019?
  • Add your answer